Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Efficacy was evaluated in FELIX (ClinicalTrials.gov. Identifier: NCT04404660), an open-label, multicenter, single-arm trial that enrolled adults with relapsed or